Blackbird Ventures

Blackbird Ventures has spent more than a decade establishing itself as the leading Australasian venture capital firm, operating from Sydney with substantial activity across both Australia and New Zealand. The firm has backed many of the most consequential technology companies to emerge from the region and runs one of the largest funds in the local ecosystem, with a thesis that explicitly seeks out what the partnership describes as wild hearts, meaning founders building ambitious global companies from a region that has historically been underestimated by international venture capital.

Within healthcare the firm has concentrated on AI and machine learning applications, biotech, and health IT, with HarrisonAI as a recognizable example of the kind of company Blackbird is willing to back at substantial scale across multiple rounds. The thesis emphasizes founders whose technical or scientific differentiation can translate into globally relevant companies rather than products optimized for the relatively small Australian and New Zealand domestic markets. AI-driven clinical software is a category of particular activity, with Blackbird willing to underwrite the long arcs that meaningful clinical AI companies require.

Check sizes typically fall in the one to five million dollar range at entry, with the firm participating from pre-seed through Series C and follow-on capacity that scales meaningfully in conviction positions. Geographic focus is Australia and New Zealand with selective activity in companies that maintain ANZ founders or operations even when headquartered elsewhere. Blackbird’s scale allows it to lead from formation through later rounds in the same company, which is a structural advantage in the relatively thin ANZ venture ecosystem where syndicate partners can be hard to assemble.

The team is large by ANZ standards and structured into sector-focused groups, supported by an operational platform that includes talent, marketing, and portfolio support functions that more closely resemble the platform operations of US tier one firms than typical regional VCs. That orientation reflects Blackbird’s aspiration to build an Australasian VC that can compete on platform value with global peers rather than compete only on geographic proximity to local founders.

For founders, Blackbird is the natural default first call in Australia and New Zealand for ambitious technology companies, including those in AI healthcare. The firm’s introductions are most valuable for international expansion, particularly into the United States, and for downstream fundraising with global investors who follow Blackbird’s leads with relative consistency. Post-investment engagement is hands-on at the early stages and steady through later rounds, with partners taking board seats and engaging actively on hiring, fundraising, and strategic decisions. Founders comfortable with high accountability and a high tempo will find the cultural fit strong, while those preferring lighter-touch investors may find the firm’s expectations demanding. For AI in healthcare, biotech, and health IT founders in ANZ building genuinely global companies, Blackbird is the firm against which other options are usually measured.